Tefferi A, Abdelmagid M, Palmer JM, Al-Kali A, et al. Post-FDA Approval Experience With Momelotinib in JAK Inhibitor-Naive Myelofibrosis: Focus on Anemia Response and Treatment-Emergent Nephropathy and Peripheral Neuropathy. Am J Hematol 2026 Jan 8. doi: 10.1002/ajh.70203.
PMID: 41504170